🔗 Share this article

This year's Nobel Prize in medical science was awarded for transformative discoveries that illuminate how the immune system targets dangerous pathogens while protecting the body's own cells.

A trio of esteemed researchers—from Japan Shimon Sakaguchi and American experts Mary Brunkow and Dr. Ramsdell—share this accolade.

Their research uncovered unique "sentinels" within the immune system that eliminate malfunctioning immune cells that could harming the body.

These findings are now enabling new therapies for autoimmune diseases and cancer.

These laureates will share a prize fund valued at 11 million SEK.

Crucial Findings

"Their research has been essential for understanding how the immune system functions and the reason we don't all suffer from serious autoimmune diseases," stated the chair of the Nobel Committee.

This trio's research address a fundamental question: In what way does the defense system defend us from countless infections while leaving our healthy cells intact?

The immune system uses immune cells that search for signs of disease, even viruses and bacteria it has never encountered.

These cells utilize sensors—called recognition units—that are produced randomly in a vast number of combinations.

This provides the immune system the ability to fight a wide array of threats, but the randomness of the mechanism inevitably creates white blood cells that may attack the body.

Security Guards of the Immune System

Researchers earlier knew that some of these harmful defense cells were destroyed in the immune organ—the site where immune cells mature.

This year's award recognizes the identification of regulatory T-cells—described as the immune system's "peacekeepers"—which travel through the body to disarm other immune cells that assault the body's own tissues.

It is known that this process fails in autoimmune diseases such as type-1 diabetes, multiple sclerosis, and rheumatoid arthritis.

The Nobel panel added, "These discoveries have laid the foundation for a new field of research and spurred the development of new treatments, for instance for cancer and autoimmune diseases."

In malignancies, regulatory T-cells prevent the system from fighting the growth, so research are focused on reducing their quantity.

For self-attack disorders, trials are testing boosting regulatory T-cells so the body is not under attack. A comparable approach could also be useful in minimizing the chances of transplanted organ rejection.

Pioneering Studies

Prof Shimon Sakaguchi, of Osaka University, conducted tests on mice that had their immune gland removed, leading to self-attack conditions.

He showed that introducing immune cells from healthy mice could prevent the illness—suggesting there was a mechanism for blocking defenders from attacking the body.

Dr. Brunkow, affiliated with the a research center in Seattle, and Dr. Ramsdell, currently at Sonoma Biotherapeutics in a California city, were investigating an genetic autoimmune disease in mice and people that resulted in the discovery of a genetic factor vital for how regulatory T-cells operate.

"The groundbreaking research has uncovered how the body's defenses is controlled by regulatory T cells, preventing it from mistakenly attacking the body's own tissues," commented a prominent biological science expert.

"This research is a remarkable illustration of how basic physiological study can have far-reaching implications for human health."